一位 Mylan Laboratories 公司的官員要求美國國會遏制品牌藥公司銷售授權(quán)非專利藥，從而保護仿制藥商,。 Mylan 公司的 Heather Bresch 說,，授權(quán)非專利藥是“削弱”仿制藥業(yè)的一種策略，他還說如果沒有來自于仿制藥的競爭,，品牌藥公司將永遠不會提供低價的替代產(chǎn)品,。
---更多詳情 The Washington Post /Reuters
Congress urged to clear path for generic drugs
By Susan Heavey
Reuters
Thursday, July 20, 2006; 7:14 PM
WASHINGTON (Reuters) - Congress should act to
protect generic drugmakers from brand-name company
tactics that thwart competition and keep cheaper
medicines from U.S. consumers,
a generic manufacturer said on Thursday.
